These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1835311)

  • 1. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen.
    Vreden SG; Verhave JP; Oettinger T; Sauerwein RW; Meuwissen JH
    Am J Trop Med Hyg; 1991 Nov; 45(5):533-8. PubMed ID: 1835311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
    Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells.
    Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R
    Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Plasmodium falciparum malaria vaccine candidate which contains epitopes from the circumsporozoite protein and a blood stage antigen, 5.1.
    Caspers P; Etlinger H; Matile H; Pink JR; Stüber D; Takács B
    Mol Biochem Parasitol; 1991 Aug; 47(2):143-50. PubMed ID: 1719416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.
    Nardin EH; Oliveira GA; Calvo-Calle JM; Wetzel K; Maier C; Birkett AJ; Sarpotdar P; Corado ML; Thornton GB; Schmidt A
    Infect Immun; 2004 Nov; 72(11):6519-27. PubMed ID: 15501783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide.
    Pessi A; Valmori D; Migliorini P; Tougne C; Bianchi E; Lambert PH; Corradin G; Del Giudice G
    Eur J Immunol; 1991 Sep; 21(9):2273-6. PubMed ID: 1889465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite.
    von Brunn A; Früh K; Müller HM; Zentgraf HW; Bujard H
    Vaccine; 1991 Jul; 9(7):477-84. PubMed ID: 1716808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards a malaria vaccine: what is in sight?
    del Giudice G
    Allergol Immunopathol (Madr); 1991; 19(3):129-35. PubMed ID: 1799171
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.
    Doherty JF; Pinder M; Tornieporth N; Carton C; Vigneron L; Milligan P; Ballou WR; Holland CA; Kester KE; Voss G; Momin P; Greenwood BM; McAdam KP; Cohen J
    Am J Trop Med Hyg; 1999 Dec; 61(6):865-8. PubMed ID: 10674660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.
    Millet P; Campbell GH; Sulzer AJ; Grady KK; Pohl J; Aikawa M; Collins WE
    Am J Trop Med Hyg; 1993 Mar; 48(3):424-31. PubMed ID: 7682382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.
    Nardin E; Munesinghe YD; Moreno A; Clavijo P; Calle MC; Edelman R; Davis J; Herrington D; Nussenzweig RS
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():223-7. PubMed ID: 1364202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast.
    Moelans II; Cohen J; Marchand M; Molitor C; de Wilde P; van Pelt JF; Hollingdale MR; Roeffen WF; Eling WM; Atkinson CT
    Mol Biochem Parasitol; 1995 Jun; 72(1-2):179-92. PubMed ID: 8538688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [NANP]19-5.1. A malaria vaccine field trial in Nigerian children.
    Reber-Liske R; Salako LA; Matile H; Sowunmi A; Stürchler D
    Trop Geogr Med; 1995; 47(2):61-3. PubMed ID: 8592764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malaria vaccines.
    Romero P
    Curr Opin Immunol; 1992 Aug; 4(4):432-41. PubMed ID: 1388845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for antibody recognition of the NANP repeats in
    Oyen D; Torres JL; Wille-Reece U; Ockenhouse CF; Emerling D; Glanville J; Volkmuth W; Flores-Garcia Y; Zavala F; Ward AB; King CR; Wilson IA
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10438-E10445. PubMed ID: 29138320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela.
    Noya O; Gabaldón Berti Y; Alarcón de Noya B; Borges R; Zerpa N; Urbáez JD; Madonna A; Garrido E; Jimenéz MA; Borges RE
    J Infect Dis; 1994 Aug; 170(2):396-402. PubMed ID: 8035026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.